← Back to Search

Immunomodulator

1 for Non-Small Cell Lung Cancer (FORTIS-C Trial)

Phase 3
Waitlist Available
Research Sponsored by Agennix
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the time of final analysis
Awards & highlights

FORTIS-C Trial Summary

The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone

Eligible Conditions
  • Non-Small Cell Lung Cancer

FORTIS-C Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after the occurence of the required number of events
This trial's timeline: 3 weeks for screening, Varies for treatment, and after the occurence of the required number of events for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival
Progression free survival
Secondary outcome measures
Objective response and disease stabilization rate
Safety and tolerability

FORTIS-C Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 1Experimental Treatment1 Intervention
Talactoferrin, Carboplatin, Paclitaxel
Group II: 2Placebo Group1 Intervention
Placebo, Carboplatin, Paclitaxel
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Talactoferrin alfa
Not yet FDA approved

Find a Location

Who is running the clinical trial?

AgennixLead Sponsor
19 Previous Clinical Trials
3,039 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
2009. "Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00706862.
All > Lung > Sclc
~68 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top